Literature DB >> 23710299

Gender differences related to the presence of atrial fibrillation in older hypertensive patients.

Lorenzo Fácila1, Vicente Pallarés, Pedro Morillas, Alberto Cordero, Jose Luis Llisterri, Carlos Sánchis, Jose L Gorriz, Jesus Castillo, Vicente Gil, Josep Redon.   

Abstract

AIM: To determine whether there are gender differences in the epidemiological profile of atrial fibrillation (AF) and to characterise the clinical, biochemical, and therapeutic factors associated with AF.
METHODS: Each investigator (primary care physicians or physicians based in hospital units for hypertension treatment) recruited the first 3 patients with an age of ≥ 65 years and a clinical diagnosis of hypertension (ambulatory blood pressure monitoring and an electrocardiogram, were performed) on the first working day of the week for 5 wk and identified those individuals with atrial fibrillation. A binary logistic regression was performed, including all of the variables that were significant in the univariate analysis, to establish the variables that were associated with the presence of arrhythmia.
RESULTS: A total of 1028 patients were included in the study, with a mean age of 72.8 ± 5.8 years. Of these patients, 47.3% were male, 9% were smokers, 27.6% were diabetics, 48.3% had dyslipidaemia, 10.9% had angina, and 6.5% had experienced a myocardial infarction. Regarding gender differences, the men exhibited a larger waist circumference, a lower body mass index, less obesity, and a more extensive history of diabetes, smoking, ischaemic heart disease, kidney failure, peripheral arterial disease and carotid disease than the women. There were no differences, however, in the prevalence of AF between the men and the women (11.5% vs 9.2%, respectively; P = no significant). Regarding treatment, the women received antiplatelet agents and diuretics less frequently, but there were no other differences in the use of antihypertensive and antithrombotic therapies. In the multivariate analysis, AF in the total study population was associated with age, alcohol consumption, the presence of heart disease, and decreased glomerular filtration. In the women, AF was associated with all of the factors included in the overall analysis, as well as the presence of left ventricle hypertrophy. In contrast, in the men, the only risk factors associated with AF were age, the presence of heart disease and alcohol consumption.
CONCLUSION: In patients with hypertension over 65 years of age, there are relevant gender differences in the factors associated with AF.

Entities:  

Keywords:  Atrial fibrillation; Gender differences; Hypertension

Year:  2013        PMID: 23710299      PMCID: PMC3663126          DOI: 10.4330/wjc.v5.i5.124

Source DB:  PubMed          Journal:  World J Cardiol


  24 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  [Prevalence of atrial fibrillation in the Spanish population aged 60 years or more. The PREV-ICTUS study].

Authors:  Luis Cea-Calvo; Josep Redón; José V Lozano; Cristina Fernández-Pérez; Juan C Martí-Canales; José L Llisterri; Jorge González-Esteban; José Aznar
Journal:  Rev Esp Cardiol       Date:  2007-06       Impact factor: 4.753

4.  Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation.

Authors:  Nikolaos Dagres; Robby Nieuwlaat; Panos E Vardas; Dietrich Andresen; Samuel Lévy; Stuart Cobbe; Dimitrios Th Kremastinos; Günter Breithardt; Dennis V Cokkinos; Harry J G M Crijns
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

5.  Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: the Belgrade atrial fibrillation study.

Authors:  Tatjana S Potpara; Jelena M Marinkovic; Marija M Polovina; Goran R Stankovic; Petar M Seferovic; Miodrag C Ostojic; Gregory Y H Lip
Journal:  Int J Cardiol       Date:  2011-05-12       Impact factor: 4.164

6.  Impact of new criteria for anticoagulant treatment in atrial fibrillation.

Authors:  Moisés Rodríguez-Mañero; Alberto Cordero; Vicente Bertomeu-González; José Moreno-Arribas; Vicente Bertomeu-Martínez; Pilar Mazón; Lorenzo Fácila; Juan Cosín; Iñaki Lekuona; Enrique Galve; José R González-Juanatey
Journal:  Rev Esp Cardiol       Date:  2011-06-08       Impact factor: 4.753

7.  Sex differences in the treatment of patients with atrial fibrillation: population-based study in a local health district.

Authors:  Alba Riesgo; Elisenda Sant; Luisa Benito; Jordi Hoyo; Oscar Miró; Lluís Mont; Ernest Bragulat; Blanca Coll-Vinent
Journal:  Rev Esp Cardiol       Date:  2011-02-15       Impact factor: 4.753

8.  [Permanent atrial fibrillation in heart disease in Spain. The CARDIOTENS study 1999].

Authors:  José María García-Acuña; José Ramón González-Juanatey; Eduardo Alegría Ezquerra; Isidoro González Maqueda; José Luis Listerri
Journal:  Rev Esp Cardiol       Date:  2002-09       Impact factor: 4.753

Review 9.  A review on sex differences in stroke treatment and outcome.

Authors:  P Appelros; B Stegmayr; A Terént
Journal:  Acta Neurol Scand       Date:  2009-11-30       Impact factor: 3.209

Review 10.  The risk of alcohol.

Authors:  P Anderson; A Cremona; A Paton; C Turner; P Wallace
Journal:  Addiction       Date:  1993-11       Impact factor: 6.526

View more
  1 in total

1.  Effects of body mass index on risks for ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation patients: a single-center experience.

Authors:  Hai-Jun Wang; Quan-Jin Si; Zhao-Liang Shan; Yu-Tao Guo; Kun Lin; Xiao-Ning Zhao; Yu-Tang Wang
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.